Update: this study is closed to enrollment.
The Weill Cornell Lymphoma Program is enrolling patients in a clinical trial testing the experimental drug CAL-101. The study evaluates the efficacy and safety of CAL-101 in patients with previously treated indolent Non-Hodgkin Lymphoma (iNHL) that is refractory both to rituximab and to alkylating-agent-containing chemotherapy. The principal investigator at Weill Cornell is Dr. Peter Martin.
All cells in the body receive signals to grow and survive, but sometimes these signals can get out of control, causing too much cell growth. When cell growth gets out of control, cancers like iNHL can develop. CAL-101 blocks some of the cell functions that cause iNHL to grow and survive. By blocking these functions, CAL-101 may reduce or prevent iNHL from growing and surviving. Results from earlier studies suggest that CAL-101 may help control iNHL.
This is a clinical trial for people with the following types of B-cell indolent non-Hodgkin lymphoma (iNHL):
- follicular lymphoma
- small lymphocytic lymphoma
- lymphoplasmacytoid lymphoma
- marginal zone lymphoma
Study participants must have received at least 2 different prior treatments for iNHL, and at some point during prior therapy they must have received rituximab and a type of chemotherapy called an alkylating agent.
The purpose of the study is to determine whether the investigational drug CAL-101 is safe and effective for treating people with iNHL once their iNHL has become too difficult to control with available therapies.
CAL-101 is a tablet. Study participants will take CAL-101 twice per day. Participants will be seen for study visits:
- every 2 weeks for the first 12 weeks of study treatment
- every 4 weeks until Week 24
- every 6 weeks until Week 48
- every 12 weeks until the end of the study
For more information, please call June Greenberg, RN at (212) 746-2651 or email June at email@example.com.